SCHEMBL25680360

SCHEMBL25680360

CC(C)C(=O)C(C)CCCN

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 3/20 0.44
CPB2 Q96IY4 3/20 0.39
GSR P00390 1/20 0.37
CA1 P00915 2/20 0.35
RNPEP Q9H4A4 1/20 0.35
LTA4H P09960 1/20 0.35
PAOX Q6QHF9 1/20 0.34
BLM P54132 2/20 0.34
GABBR2 O75899 3/20 0.33
GABBR1 Q9UBS5 3/20 0.33
GABRR3 A8MPY1 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
HDAC3 O15379 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
THRB P10828 1/20 0.33
GABRA1 P14867 1/20 0.33
TSHR P16473 1/20 0.33
GABRB1 P18505 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14336273 0.93 GSR (0.45) GABRR1CPB2GSRCA1RNPEP
SCHEMBL21103899 0.93 GSR (0.45) GABRR1CPB2GSRCA1RNPEP
SCHEMBL14336426 0.93 GSR (0.45) GABRR1CPB2GSRCA1RNPEP
SCHEMBL21400114 0.91 GSR (0.43) GABRR1CPB2GSRCA1RNPEP
SCHEMBL15604284 0.85 GABRR1 (0.61) GABRR1GSRGABBR2GABBR1GABRP
SCHEMBL17465211 0.85 GABRR1 (0.61) GABRR1GSRGABBR2GABBR1GABRP
SCHEMBL18236077 0.85 GABRR1 (0.61) GABRR1GSRGABBR2GABBR1GABRP
SCHEMBL24804495 0.79 GABRR1 (0.38) GABRR1CPB2GSRRNPEPPAOX
SCHEMBL14750474 0.79 GABRR1 (0.38) GABRR1CPB2GSRRNPEPPAOX
SCHEMBL12278737 0.79 GSR (0.50) GABRR1CPB2GSRGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds SYNEDGEN, INC. (US) 2023-10-17 US disclosed
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds SYNEDGEN, INC. (US) 2023-08-08 US disclosed
US-20230167148-A1 MODULAR SYNTHESIS OF AMINOGLYCOSIDES REVAGENIX, INC. 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167148-A1 MODULAR SYNTHESIS OF AMINOGLYCOSIDES MRPL21, COASY, AARS1 GABRR1 3935/4885CPB2 2825/4885GSR 2369/4885
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds CHIA, MMP8, CHIT1 GABRR1 3639/4885CPB2 595/4885GSR 2485/4885
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds CHIT1, ALG1, CSGALNACT1 GABRR1 1985/4885CPB2 325/4885GSR 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.